Top headlines: Covaxin cheaper than Covoshield; spectrum auction from Mar 1

From government working on pricing of the coronavirus vaccine to decks being cleared for Container Corporation privatisation, here are top headlines this morning

Bharat Biotech vaccine may cost less than Serum's; govt working on pricing

Ahead of the massive inoculation drive starting next week, the government is engaged with the vaccine makers to discuss their final pricing, according to people in the know. They indicated that Hyderabad-based player Bharat Biotech could price its indigenous candidate Covaxin lower than Covishield—the AstraZeneca-Oxford vaccine manufactured by Serum Institute of India. The final contract is expected to be signed soon. Pricing took time as the government tried to get the best deal possible for the initial roll out. Read More

Govt to hold spectrum auctions